Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1186/s12885-025-13577-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction: EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis.
BMC Cancer
January 2025
Department of Respiratory Medicine, Chengdu BOE Hospital, Chengdu, Sichuan Province, 610000, China.
Class I HLA Alleles Are Associated With an Increased Risk of Osimertinib-Induced Hypersensitivity.
J Allergy Clin Immunol Pract
January 2025
Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taipei, and Keelung, Taiwan; Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan; Chang Gung Immunology Consortium, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan; Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China; Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung, Taiwan; Immune-Oncology Center of Excellence, Chang Gung Memorial Hospital, Linkou, Taiwan; Department of Dermatology, Beijing Tsinghua Chang Gung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China; Department of Dermatology, Ruijin Hospital, School of Medicine, Shanghai Jiao-tong University, Shanghai, China; Genomic Medicine Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan. Electronic address:
Article Synopsis
- - Osimertinib is an effective lung cancer drug, but it can cause severe allergic reactions, especially in Asian patients, which can complicate treatment.
- - A study of 17 patients showed that the genetic marker HLA-B*51:02 was found in a high percentage of those experiencing severe allergic reactions (SJS/TEN), indicating a strong genetic predisposition.
- - The presence of HLA-B*51:02 also correlated with higher levels of a specific protein related to these reactions, suggesting that individuals with this genetic marker may be at risk for severe side effects when taking osimertinib.
Impact of sequential (first- to third-generation) EGFR-TKI treatment on corrected QT interval in NSCLC patients.
Front Oncol
May 2024
Department of Cardiology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Objective: To evaluate the impact of sequential (first- to third-generation) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment on top-corrected QT interval (top-QTc) in non-small cell lung cancer (NSCLC) patients.
Methods: We retrospectively reviewed the medical records of NSCLC patients undergoing sequential EGFR-TKI treatment at Shanghai Chest Hospital between October 2016 and August 2021. The heart rate (HR), top-QT interval, and top-QTc of their ECGs were extracted from the institutional database and analyzed.
Discovery of new thieno[2,3-]pyrimidines as EGFR tyrosine kinase inhibitors for cancer treatment.
Future Med Chem
July 2023
Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt.
EGFR has been considered a vital molecular target in cancer management. The discovery of new thieno[2,3-]pyrimidine derivatives as EGFR tyrosine kinase inhibitors. Nine derivatives were designed, synthesized and subjected to and studies.
View Article and Find Full Text PDFRetrospective study of EGFR-mutant lung adenocarcinoma with bone metastatic clinical features.
Cancer Rep (Hoboken)
January 2023
Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin, PR China.
Background: With more and more target medicine application in lung cancer, lots of patients take medicine at home, the treatment bone metastasis and screen of bone metastasis always has been neglected until skeletal-related events (SREs) such as bone pain, hypercalcemia of malignancy and pathologic fractures emerging which significantly impairs the patients' daily activity ability, seriously lower quality of life.
Aim: To identify the clinical characteristics of patients which influence the overall survival (OS) of EGFR-TKIs effective in EGFR-mutant NSCLC with bone metastasis (BM) and the bone metastatic image features.
Methods: We conducted a retrospective study in patients (treated with EGFR-TKIs ≥6 months) of lung adenocarcinoma with BM in our hospital from October 2014 to October 2017.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!